Cargando…
Proteasome Inhibitor MG132 Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells and Inhibits Tumor Growth
Although cisplatin has been shown to be an integral part of chemotherapy regimen in osteosarcoma (OS) treatment, toxicity issues and chemoresistance have hindered therapeutic development for OS. Exploring novel combination therapy methods is needed to circumvent the limitations of cisplatin alone. T...
Autores principales: | Sun, Farui, Zhang, Yuanjin, Xu, Lijun, Li, Songbai, Chen, Xiang, Zhang, Ling, Wu, Yifan, Li, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cognizant Communication Corporation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844646/ https://www.ncbi.nlm.nih.gov/pubmed/29191257 http://dx.doi.org/10.3727/096504017X15119525209765 |
Ejemplares similares
-
Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells
por: DANG, LIFENG, et al.
Publicado: (2014) -
The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish
por: Winder, Steve J, et al.
Publicado: (2011) -
Proteasome inhibitor MG-132 induces MCPIP1 expression
por: Skalniak, Lukasz, et al.
Publicado: (2013) -
Effects of proteasome inhibitor MG-132 on the parasite Schistosoma mansoni
por: Morais, Enyara R., et al.
Publicado: (2017) -
Systemic Perturbation of the ERK Signaling Pathway by the Proteasome Inhibitor, MG132
por: Cirit, Murat, et al.
Publicado: (2012)